New diagnose is with of early gastric cancer for recurred surgical operation that uses shortening midkine is necessary.

对于早期胃癌的新诊断，使用缩短中期因子的复发性手术是必要的。

• 批准号: 20590812
• 负责人: ITOH Tohru
• 金额: $ 3.16万
• 依托单位: Kanazawa Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20590812/
• 关键词: 早期胃癌; 短縮ミッドカイン; 内視鏡治療; 酵素抗体法

This study was carried out about early gastric cancer (sm gastric cancer) in the following items and conducted the examination that could not search lymph node metastases before treatment.1.The manufacture of the antitMK monoclonal antibody and detectability and specific confirmation2.Detection 3 of onset with the gastric cancer cell line of analysis tMKmRNA and the tMK protein.As a result, the significant difference of the thing which tended to be strong in sm2 which was deep as for the onset of tMK by the difference of depth of sm1 and sm2 in the sm cancer depth was not clear the analysis in the tMK monoclonal antibody with the early gastric cancer (sm1,sm2) resected specimen which was the clinical specimen of the human and onset of tMKmRNA and protein analysis.Also, with the biopsy tissue of the case with lymph node metastases, a preoperative biopsy, expression of tMK in lymph nodes were not able to find the association.

本研究对早期胃癌（sm胃癌）进行了以下项目的研究，并在治疗前进行了无法搜索淋巴结转移的检查。抗tmk单克隆抗体的制备、可检测性及特异性证实3 .用胃癌发病细胞系检测分析tMKmRNA和tMK蛋白。因此，在tMK单克隆抗体与人类临床标本早期胃癌（sm1、sm2）切除标本及tMKmRNA和蛋白的发病分析中，sm1和sm2在smk癌变深度的差异中，sm2深部倾向强的事物与tMK发病的显著性差异并不明显。此外，对于淋巴结转移病例的活检组织，术前活检，淋巴结中tMK的表达未能发现相关性。